

Information Posted on the Site

<Proposed Technology>

No	Item	Contents	Basic Information	Detailed Information	Application of the Category
1	Category of Proposed Technology	Select the pertinent one out of By (A) Drug Seeds/Drug Targets, (B) Platform Technology, (C) Biomarkers/Diagnostics/Reagents, (D) Foods/Cosmetics	◎		ALL
2	Treatment Area (Target disease)	Select the pertinent one out of (1) By Target disease: "Allergic Disease" "Bone and Joint Disease" "Cancer" "Cardiovascular Disease" "Central nervous system Disease" "Dermatological Disease" "Gastrointestinal Disease" "Immunological Disease" "Infectious Disease" "Inflammatory Disease" "Metabolic Disease" "Ophthalmologic Disease" "Pain Disorder" "Respiratory Disease" "Urinary tract Disease" "Others"	◎		(A), (C)
	Treatment Area (Treatment part) Notice: Only "cancer" is selected in Treatment Parts. Please select "others" if you don't select "cancer".	Select the pertinent one out of (1) By Treatment part: "Blood" "Bone" "Brain" "Breast" "Digestive organ" "Endocrine Organ" "Genitals (prostate, uterus, ovary)" "Kidney" "Liver" "Muscle" "Pancreas" "Skin" "Urinary organs (bladder)" "Others"	◎		(A), (C)
4	Titles of Proposed Technology	Describe the title to the extent that the name of affiliated organization/corporation is not identifiable.		◎	ALL

5	Outline of the Technology	Describe outline of Proposed Technology in a sentence		◎	ALL
6	Holding Compound	Select the pertinent one out of (1) By “New compound” ”Research tool” ”none”		◎	(A), (C)
7	Development Stage	Select the pertinent one out of “In vitro” “In vivo” “Optimization phase” “Immediately preceding clinical test (one that starts clinical test within one (1) year)” “Phase I” “Phase II and/or later stage”		◎	(A), (C)
8	Preferred method of partnering	Select the pertinent one out of “Sales of Patent” “License (Exclusive License)” “License (Non-exclusive License)” “Joint Research” “Subject to Negotiation” and “Other” (multiple answers acceptable).		◎	(A), (C)
9	Patent acquisition of research findings	Select the pertinent one out of "Already Patented" "Already Filed" "Under Study"		◎	(A), (C)
10	Category of Affiliation	Select the pertinent one out of “University/Research Institute” “Technology Licensing Organization (TLO)” “Pharmaceutical Company” “Venture Company” “General Company” “Individual” and “Other”	◎		ALL
11	Location of Affiliated Organization/Corporation	Select the pertinent one out of “Japan” “Asia” “North America” “EU” and “Other”		◎	ALL
12	Contact person Information	Describe contact persons “name” and “Mail address”	-	-	ALL
13	Publication Number JPA Publication Number WO	Describe Patent Publication Number		○	ALL
14	Title of Invention	Describe “Title of Invention”		○	ALL
15	Applicant Name	Describe “Applicant Name”		○	ALL
16	Inventor Name	Describe “Inventor Name”		○	ALL
17	Additional Data of the technology	Attach “additional data of the technology”		○	ALL
18	Image1	Attach “Image1” data (JPEG, GIF)		○	
19	Image2	Attach “Image2” data (JPEG, GIF)		○	ALL
20	Image3	Attach “Image3” data (JPEG, GIF)		○	ALL
21	Principal Type of Patent	Select the pertinent one out of “Substance Patent” “Process Patent” “Application Patent” “Formulation Patent” and “Other”		○	ALL

22	Country where Patents are (to be) acquired	<p>>> Select the pertinent one out of the status of patent acquisition for each country in accordance with the following form.</p> <p>Ex.) Japan: Expected acquisition: “Yes” “No” Status of acquisition: “Before application” “Applied” “acquired”</p> <p>The same description shall be made for the United States, UK, Germany and France.</p> <p>Acquired in a total of X countries around the world (including expected Acquisition).</p> <p>>> Enter the patent number for each country where the patent is acquired in accordance with the following form (if not, leave it blank).</p> <p>Ex.) Japan: Patent No. XXXXXXXXX</p> <p>The same entry shall be made for the United States, UK, Germany and France.</p> <p>>> Enter the expiry date for each country where the patent is acquired in accordance with the following form (if not, leave it blank).</p> <p>Ex.) Japan: Date: XXX XX, XXXX (in AD)</p> <p>The same entry shall be made for the United States, UK, Germany and France.</p>		○	ALL
23	Comment on Patent	Describe in a sentence the comment on the overall patents.		○	ALL
24	Target Diseases	Describe Target diseases by itemization		○	ALL
25	Market Size, etc.	Describe in a sentence expected market size		○	ALL
26	Action Mechanism	Describe in a sentence the action mechanism		○	ALL
27	Administration Method	Select the pertinent one out of “Oral” “IV Injection” “Transdermal” “Instillation” “Nasal Drip” and “Other”		○	ALL
28	Reasons for Discontinued Development	Describe in a sentence the reasons for discontinued development		○	ALL
29	Safety/Toxicity	Describe the scope of safety		○	ALL
30	In Vitro Test Results	Describe in a sentence the In vitro test results		○	ALL
31	In Vivo Test Results	Describe in a sentence the In vivo test results		○	ALL
32	Manufacturing Know-How	Select the pertinent one whether it has manufacturing know-how.		○	ALL
33	Comment on Manufacturing Know-How	Describe in a sentence the comment on the above.		○	ALL
34	Samples	Select the pertinent one whether it has samples or not.		○	ALL
35	Comment on Samples	Describe in a sentence the comment on the above, if any.		○	ALL
36	Assessment Data	Select the pertinent one whether it has assessment data or		○	ALL

		not.			
37	Comment on Assessment Data	Describe in a sentence the comment on the above, if any.		○	ALL
38	Minimum Lump-sum contact Money Desired	Select the desired amount out of less than ¥ 1 million, over ¥1 million, over ¥3 million, over ¥5 million, over ¥10 million, over ¥30 million, and over ¥50 million.		○	ALL
39	Other Information	Describe in a sentence the matters the information of which will be provided, if any.		○	ALL

* ◎: Essential, ○: Voluntary entry items